Kronos Bio, Inc.
KRONDelisted Jun 20, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001741830
Kronos Bio, Inc. was delisted on Jun 20, 2025; its insiders filed their last Form 4 on Jun 20, 2025; 47 institutions reported holding it in 13F filings for Q1 2025, worth $15.8M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 47
- Q1 2025, −9 vs. previous quarter
- 13F value
- $15.8M
- Reported value at the end of Q1 2025
- Superinvestors holding
- 0
- At the end of Q1 2025
Superinvestors holding KRON, Q1 2025
No superinvestor reported holding KRON at the end of Q1 2025.
Latest insider trades
Open-market purchases and sales by Kronos Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2025 (view filing) | Jun 5 | 1 day | Knobelman DeborahPresident & Interim CEO | SSale | −24.8K | $0.87 | −$21.6K | −15.1%139.4K after | |
| Jul 1, 2024 (view filing) | Jun 27-28 | 4 days | Bischofberger Norbert WPRESIDENT & CEO | PPurchase | +615.5K | $1.20 | +$736.5K | +6.0%10.8M after | 2 lots |
| Jun 12, 2024 (view filing) | Jun 10-12 | 2 days | Bischofberger Norbert WPRESIDENT & CEO | PPurchase | +3.01M | $1.04 | +$3.12M | +68.8%7.38M after | 3 lots |
| Feb 23, 2024 (view filing) | Feb 21 | 2 days | Olek Elizabeth ASR VP, CLINICAL SCIENCE | SSale | −7.37K | $1.05 | −$7.74K | −3.7%193.3K after | |
| Feb 23, 2024 (view filing) | Feb 21 | 2 days | Lin Charles YSR VP, RESEARCH & DEVELOPMENT | SSale | −12.0K | $1.05 | −$12.6K | −4.9%234.6K after | |
| Feb 23, 2024 (view filing) | Feb 21 | 2 days | Frisbee AllisonSR VP, CORP OPERATIONS & LEGAL | SSale | −12.1K | $1.05 | −$12.7K | −5.6%204.5K after | |
| Jan 5, 2024 (view filing) | Jan 4 | 1 day | Dinsmore ChristopherChief Scientific Officer | SSale | −7.37K | $1.18 | −$8.69K | −2.7%261.0K after | |
| Jan 5, 2024 (view filing) | Jan 4 | 1 day | DiMartino JorgeChief Medical Officer & VP | SSale | −12.0K | $1.18 | −$14.2K | −3.7%315.2K after | |
| Jan 5, 2024 (view filing) | Jan 4 | 1 day | Kosacz BarbaraCOO & General Counsel | SSale | −10.7K | $1.18 | −$12.6K | −1.1%929.0K after | |
| Dec 13, 2023 (view filing) | Dec 12 | 1 day | Dinsmore ChristopherChief Scientific Officer | SSale | −10.0K | $1.31 | −$13.1K | −3.6%268.3K after |
Top 10 13F holders, Q1 2025
The largest institutional positions in Kronos Bio, Inc. at the end of Q1 2025; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,765,314 | $2.28M | 16.73% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,922,809 | $1.59M | 0.00% | 00.0% | Unchanged |
| Partners Capital Investment Group, LLP | 1,448,654 | $1.20M | 0.02% | +921,154+174.6% | Added |
| Alphabet Inc. | 1,438,232 | $1.19M | 0.08% | 00.0% | Unchanged |
| Millennium Management LLC | 1,425,065 | $1.18M | 0.00% | −291,436−17.0% | Reduced |
| Tang Capital Management LLC | 1,345,413 | $1.11M | 0.06% | +342,031+34.1% | Added |
| Wildcat Capital Management, LLC | 1,297,959 | $1.07M | 0.57% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 1,230,770 | $1.01M | 0.00% | −73,741−5.7% | Reduced |
| Renaissance Technologies LLC | 1,102,326 | $909.4K | 0.00% | −69,482−5.9% | Reduced |
| Siren, L.L.C. | 842,954 | $695.4K | 0.04% | 00.0% | Unchanged |